Cristina Csimma, PharmD, MHP, is a biopharmaceutical executive, independent board director, former CEO, VC, and strategic advisor for multiple biotechnology companies, NIH and patient foundations. She has extensive new company formation and financing experience and global drug development expertise.
She currently serves as an independent Board Director at Neuralstem Inc (CUR), the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee, the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network; the Rockefeller University Robertson Therapeutic Development Fund Review Committee and the TREAT-NMD Advisory Committee for Therapeutics (TACT) where she served as founding chair.
She was previously the Executive Chair of the Board of Directors of Exonics Therapeutics from inception through the $40M series A financing (December 2017); an independent Director on the Board of Juniper Pharmaceuticals (acquired by Catalent in August 2018) Committee) an independent Board Director and SAB co-chair of Vtesse Pharma (acquired in March 2017 by Sucampo Pharmaceuticals and Cydan where she was also the founding CEO and President. She also served as Venture Advisor for NEA and Atlas Ventures and served on the External Oversight Committee of NIH Blueprint Neurotherapeutics Network. Former roles were Vice President of Drug Development at Virdante Pharmaceuticals Inc., Principal at Clarus Ventures LLC, Clinical Development and Translational Research at Wyeth (now Pfizer) where she was responsible for clinical stage translational programs, Genetics Institute and Dana Farber Cancer Institute.
Dr. Csimma received her Bachelor of Science and Doctor of Pharmacy degrees from Massachusetts College of Pharmacy, and a Master of Health Professions from Northeastern University.